Circassia is a world-class specialty biopharmaceutical business focused on allergy and respiratory disease. The Company has an established commercial infrastructure, marketed products, a pipeline of near-term therapies and a portfolio of next generation treatments targeting multi-$billion market opportunities. Circassia sells its novel, market-leading products for asthma management directly to allergy / asthma specialists in the United States and Germany. Its products are also promoted in a number of other countries by the Company’s international network of partners.
Circassia’s broad-based development pipeline includes a range of treatments for allergy and respiratory disease. Circassia’s most advanced next-generation immunotherapy is currently in phase III testing for cat allergy, and is the first in a new class of treatments, Synthetic Peptide Immuno-Regulatory Epitopes (SPIREs). Three other SPIREs, targeting house dust mite, ragweed and grass allergies, have completed clinical proof-of-concept phase IIb studies. Circassia’s lead asthma product targets substitution of GSK’s FLIXOTIDE® pMDI, and UK approval is expected in December 2015. Circassia anticipates two further product filings in 2016, targeting direct substitution of SERETIDE® pMDI and SEREVENT® pMDI. The Company is also developing a number of novel treatments, including a fixed dose ‘triple’ combination containing an inhaled corticosteroid, long-acting beta agonist and long-acting muscarinic antagonist.

Company Growth (employees)
Oxford, GB
Size (employees)
204 (est)
Circassia was founded in 2006 and is headquartered in Oxford, GB

Key People/Management at Circassia

Steven Harris

Steven Harris

Charles Swingland

Charles Swingland

Deputy Chairman and General Counsel

Circassia Office Locations

Circassia has offices in Oxford, Chicago and Solna
Oxford, GB (HQ)
The Oxford Science Park
Solna, SE
18 Råsundavägen
Chicago, US
101 North Wacker Drive Suite 100

Circassia Financials and Metrics

Circassia Financials

Circassia's revenue was reported to be £17 k in FY, 2016

Revenue (FY, 2016)

17 k

Net income (FY, 2016)

17 k

EBITDA (FY, 2016)

17 k

EBIT (FY, 2016)

17 k

Market capitalization (31-Oct-2017)

255.3 m

Closing share price (31-Oct-2017)

Circassia's current market capitalization is £255.3 m.
GBPFY, 2008FY, 2009FY, 2013FY, 2014FY, 2015FY, 2016


17 k


(624.7 k)(362.3 k)(188 k)(3 k)17 k

EBITDA margin, %



(624.7 k)(362.3 k)(295 k)(3 k)17 k
GBPFY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Accounts Receivable

117.2 k104.4 k27 k1 k

Current Assets

19.6 k1117.2 k104.4 k27 k1 k

Total Assets

19.6 k1106.8 k124 k211.2 k27 k1 k

Accounts Payable

190.5 k34.6 k84.7 k154.3 k21 k
    GBPFY, 2008FY, 2009FY, 2013FY, 2014FY, 2015FY, 2016

    Net Income

    (624.7 k)(362.3 k)(269 k)(2 k)(1 k)17 k

    Income Taxes Paid

    26 k1 k(1 k)
      Show all financial metrics

      Circassia Market Value History

      Circassia's Web-traffic and Trends

      Circassia Company Life and Culture

      You may also be interested in